[EN] TARGETING COMPOUNDS<br/>[FR] COMPOSÉS DE CIBLAGE
申请人:ZAFGEN INC
公开号:WO2019118612A1
公开(公告)日:2019-06-20
The disclosure provides, at least in part, liver, intestine and/or kidney-targeting compounds and their use in treating liver, intestine and/or kidney disorders, such as non-alcoholic steatohepatitis, alcoholic steatohepatitis, hepatocellular carcinoma, liver cirrhosis, and hepatitis B; and/or chronic kidney disease, glomerular disease such as IGA nephropathy, lupus nephritis, or polycystic kidney disease. The compounds are contemplated to have activity against methionyl aminopeptidase 2.
Convenient synthesis of enantiopure (R-) and (S-)-3-fluoro-3-aminomethylpyrrolidines
作者:Vladimir S. Yarmolchuk、Vladimir L. Mykhalchuk、Pavel K. Mykhailiuk
DOI:10.1016/j.tet.2014.03.002
日期:2014.5
(R-)- and (S-)-3-fluoro-3-aminomethylpyrrolidines were synthesized from methyl alpha-fluoroacrylate in eight steps. alpha-Phenylethylamine was used as a chiral auxiliary to separate the racemic mixture. The overall synthesis yield was 31%. (C) 2014 Elsevier Ltd. All rights reserved.
Synthesis of β-fluoro-β-proline
作者:Vladimir S. Yarmolchuk、Pavel K. Mykhailiuk、Igor V. Komarov
DOI:10.1016/j.tetlet.2011.01.070
日期:2011.3
A synthetic strategy towards the novel amino acid β-fluoro-β-proline, a fluorinatedanalogue of β-proline, is elaborated. The synthesis commences from commercially available methyl 2-fluoroacrylate and involves three steps. The overall yield of β-fluoro-β-proline is 57%.